Table 4.

Baseline characteristics

CharacteristicsCohort 1/expansion (n = 31)Cohort 2a (n = 3)All patients (N = 34)
Median age, y (range)66 (41–85)55 (39–77)66 (39–85)
Age ≥65 y, n (%)18 (58)1 (33)19 (56)
Male, n (%)16 (52)2 (67)18 (53)
Median BSA, m2 (range)1.82 (1.49–2.45)2.00 (1.95–2.35)1.86 (1.49–2.45)
Histology at study entry, n (%)
MF17 (55)2 (67)19 (56)
Transformed MF10 (32)1 (33)11 (32)
Sézary syndrome3 (10)0 (0)3 (9)
Primary cutaneous ALCL, ALK1 (3)0 (0)1 (3)
ECOG performance status 0/1/2, %68/16/1667/33/068/18/15
Median number of prior therapies (range)3 (1–12)4 (3–14)3.5 (1–14)
  • Abbreviations: BSA, body surface area; MF, mycosis fungoides.